ANeuroTech

Pre-clinical

Leuven, BelgiumFounded 2016aneurotech.com

Treating Partially Responsive Depression (PRD) as an unmet medical need ANEUROTECH is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies. This established drug acts uniquely as a combined High Selective Serotonin 2A... Read more »

Founded

2016

Focus

Small Molecules

About

Treating Partially Responsive Depression (PRD) as an unmet medical need ANEUROTECH is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies. This established drug acts uniquely as a combined High Selective Serotonin 2A... Read more »

Company Info

TypePrivate

Founded2016

LocationLeuven, Belgium

StagePre-clinical

Contact

Sectors

Small Molecule Drugs Neuroscience & CNS

SIMILAR COMPANIES

Miracor Medical

Pre-clinical · Zaventem

AML Clinical Services

Pre-clinical · Leuven

Pre-clinical · Ghent

Aseptic Technologies

Pre-clinical · Gembloux

Aspect Analytics

Pre-clinical · Leuven

Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.